Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea.
OBJECTIVE
To compare glucose and rice-based oral rehydration solution with rice-based oral rehydration solution containing recombinant human lactoferrin and recombinant human lysozyme in diarrhea outcomes.


METHODS
We conducted a randomized, double-blind controlled trial in children with acute diarrhea and dehydration. One hundred and forty children 5 to 33 months old were block randomized to receive low osmolarity WHO-ORS (G-ORS), rice-based ORS (R-ORS), or rice-based ORS plus lactoferrin and lysozyme (Lf/Lz-R-ORS). Intake and output were monitored for 48 h in the ORU, with continued monitoring through home and clinic follow-up for 14 d.


RESULTS
The G-ORS and R-ORS groups did not show any differences in diarrhea outcomes and were therefore combined as the control group. Intent-to-treat analysis showed a significant decrease in duration of diarrhea (3.67 d vs 5.21 d, P = 0.05) in the Lf/Lz-R-ORS group as compared with the control group and a significant increase in the number of children who achieved 48 h with solid stool, 85% vs 69% (P < 0.05). There were no significant differences [corrected] in volume of diarrhea or [corrected] the percentage of children who had a new diarrhea episode after achieving the endpoint.


CONCLUSIONS
Addition of recombinant human lactoferrin and lysozyme to a rice-based oral rehydration solution had beneficial effects on children with acute diarrhea.
Zavaleta
Nelly
N
Instituto de Investigación Nutricional, Lima, Peru. nzavalet@iin.sld.pe
Figueroa
Dante
D
Rivera
Juan
J
Sánchez
Julia
J
Alfaro
Segundo
S
Lönnerdal
Bo
B
D000208:Acute Disease; D000284:Administration, Oral; D002675:Child, Preschool; D003681:Dehydration / Q000209:etiology / Q000628:therapy*; D003967:Diarrhea / Q000150:complications / Q000628:therapy*; D004311:Double-Blind Method; D005440:Fluid Therapy / Q000379:methods*; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D007223:Infant; D007781:Lactoferrin / Q000008:administration & dosage*; D008297:Male; D009113:Muramidase / Q000008:administration & dosage*; D012275:Oryza; D010568:Peru; D011446:Prospective Studies; D016896:Treatment Outcome
D009113:Muramidase; D007781:Lactoferrin; D005947:Glucose